DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

被引：2
作者：
Elgart, J. F. [1 ]
Prestes, M. [1 ]
Gonzalez, L. [1 ]
Aschner, P. [2 ]
Garrido Lecca, S. [3 ]
Aiello, E. [4 ]
Jimenez, C. [5 ]
Gagliardino, J. J. [1 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, Buenos Aires, DF, Argentina
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Bristol Myers Squibb Co, Lima, Peru
[4] Bristol Myers Squibb Co, Buenos Aires, DF, Argentina
[5] Bristol Myers Squibb Co, Bogota, Colombia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1442
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A247 / A247
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes
    Cai, Xiaoling
    Shi, Lizheng
    Yang, Wenjia
    Gu, Shuyan
    Chen, Yingyao
    Nie, Lin
    Ji, Linong
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 336 - 343
  • [42] COST-EFFECTIVENESS OF NIASPAN® VERSUS ZETIA® AS ADD-ON TREATMENT TO STATIN THERAPY IN HIGH-RISK PATIENTS
    Sorensen, S., V
    Webb, S. F.
    Burge, R. T.
    VALUE IN HEALTH, 2008, 11 (06) : A393 - A393
  • [43] Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: A comparative study
    Mahajan, Rajiv
    Gupta, Anita
    Gupta, Rajinder Singh
    Gupta, Kapil
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2010, 1 (02) : 82 - 86
  • [44] COST-EFFECTIVENESS OF ADD-ON THERAPIES TO METFORMIN: THE IMPACT OF MEDICATION ADHERENCE FOR TYPE 2 DIABETES MELLITUS
    Ho, C. M.
    Yeh, T. H.
    Lai, Y. T.
    VALUE IN HEALTH, 2021, 24 : S80 - S80
  • [45] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [46] Dapagliflozin as add-on to metformin; network meta-analysis and budget impact analysis
    Mannucci, Edoardo
    Torre, Enrico
    Berto, Patrizia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (03) : 125 - 134
  • [47] Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
    Driessen, Maurice
    Shah, Dhvani
    Risebrough, Nancy
    Baker, Timothy
    Naya, Ian
    Briggs, Andrew
    Ismaila, Afisi S.
    RESPIRATORY MEDICINE, 2018, 145 : 130 - 137
  • [48] Cost-effectiveness of pallidotomy and add-on medical therapy in advanced Parkinson's disease
    Siderowf, A
    Holloway, R
    Mushlin, A
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 517 - 517
  • [49] Dual therapy with inhaled human insulin (Exubera®) as add-on to metformin (with stopping sulfonylurea) is better than triple therapy with rosiglitazone add-on to combination metformin and sulfonylurea in poorly controlled type 2 diabetes
    Rosenstock, Julio
    Gross, Jorge
    Eliaschewitz, Reddy
    Mitnick, Michael
    Lawrence, David
    Canovatchel, William
    Hollander, Priscilla
    DIABETES, 2008, 57 : A557 - A557
  • [50] Cost-effectiveness analysis of the therapy for the invasive Candidiasis in Colombia
    Molina, F. J.
    Cortes, J. A.
    Caceres, H. A.
    Soto, R.
    Lemos Luengas, E. V.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E123 - E123
12345